Table 2.
Efficacy Evaluation of 59 MM Patients
| Items | NDMM (n=13) n (%) | RRMM (n=13) n (%) | Continuing Therapy (n=33) n (%) |
|---|---|---|---|
| Median follow-up (months) | 3 (1–11) | 4 (2–10) | 6 (2–11) |
| Median time to response (days) | 49 (22–108) | 59 (23–88) | 75 (25–141) |
| sCR | – | – | 9 (27.3) |
| CR | 1 (7.7) | 1 (7.7) | 15 (45.5) |
| VGPR | 5 (38.5) | 2 (15.4) | 6 (18.2) |
| PR | 4 (30.8) | 3 (23.1) | 3 (9.1) |
| MR | 1 (7.7) | 0 (0,0) | 0 (0,0) |
| SD | 1 (7.7) | 1 (7.7) | 0 (0,0) |
| PD | 1 (7.7) | 6 (46.2) | 0 (0,0) |
| ORR | 10 (76.9) | 6 (46.2) | 33 (100) |
| <65 years | 4 (100.0) | 9 (69.2) | 25 (75.8) |
| ≥65 years | 6 (66.7) | 4 (30.8) | 8 (24.2) |
| Cytogenetic high risk | 3 (100.0) | 2 (50.0) | 4 (100.0) |
| Cytogenetic standard risk | 7 (70.0) | 4 (44.4) | 29 (100.0) |
Abbreviations: NDMM, newly diagnosed multiple myeloma; RRMM, refractory/relapsed multiple myeloma; sCR, stringent complete remission; CR, complete remission; VGPR, very good partial remission; PR, partial remission; MR, minimal remission; SD, stable disease; PD, progressive disease; ORR, overall response rate (≥PR).